Healthcare provider profile · identity verified

Grayson Wells Cobb, MD

Family Practice · MISSOULA, MT · NPI 1952860991

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	322	92
Amlodipine Besylate	Amlodipine Besylate	238	67
Losartan Potassium	Losartan Potassium	212	61
Lisinopril	Lisinopril	176	46
Tamsulosin Hcl	Tamsulosin Hcl	149	39
Telmisartan	Telmisartan	144	45
Omeprazole	Omeprazole	141	49
Simvastatin	Simvastatin	140	34
Rosuvastatin Calcium	Rosuvastatin Calcium	128	35
Levothyroxine Sodium	Levothyroxine Sodium	117	31
Metformin Hcl Er	Metformin Hcl	102	28
Escitalopram Oxalate	Escitalopram Oxalate	94	20
Metoprolol Succinate	Metoprolol Succinate	92	22
Gabapentin	Gabapentin	69	23
Trulicity	Dulaglutide	64	suppressed
Trazodone Hcl	Trazodone Hcl	61	15
Eliquis	Apixaban	58	14
Albuterol Sulfate Hfa	Albuterol Sulfate	56	21
Pravastatin Sodium	Pravastatin Sodium	56	16
Hydrochlorothiazide	Hydrochlorothiazide	53	19
Jardiance	Empagliflozin	52	suppressed
Chlorthalidone	Chlorthalidone	50	16
Warfarin Sodium	Warfarin Sodium	50	13
Indapamide	Indapamide	49	16
Meloxicam	Meloxicam	49	13
Mounjaro	Tirzepatide	47	11
Allopurinol	Allopurinol	46	11
Fluticasone Propionate	Fluticasone Propionate	45	18
Sertraline Hcl	Sertraline Hcl	45	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	43	13
Potassium Chloride	Potassium Chloride	40	20
Spironolactone	Spironolactone	36	11
Donepezil Hcl	Donepezil Hcl	34	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	30	suppressed
Loperamide	Loperamide Hcl	30	suppressed
Xarelto	Rivaroxaban	30	suppressed
Carvedilol	Carvedilol	29	suppressed
Valsartan	Valsartan	29	suppressed
Ozempic	Semaglutide	26	suppressed
Bupropion Xl	Bupropion Hcl	25	11
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Topiramate	Topiramate	25	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Farxiga	Dapagliflozin Propanediol	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Finasteride	Finasteride	22	suppressed
Metformin Hcl	Metformin Hcl	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Ketoconazole	Ketoconazole	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Ondansetron Odt	Ondansetron	20	14
Furosemide	Furosemide	19	suppressed
Oxycodone Hcl	Oxycodone Hcl	19	12
Oxycontin	Oxycodone Hcl	19	suppressed
Torsemide	Torsemide	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Atenolol	Atenolol	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Estradiol	Estradiol	16	suppressed
Prednisone	Prednisone	16	13
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Glimepiride	Glimepiride	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	15	suppressed
Testosterone Cypionate	Testosterone Cypionate	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Terbinafine Hcl	Terbinafine Hcl	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	12
Acyclovir	Acyclovir	13	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Famotidine	Famotidine	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Fosinopril Sodium	Fosinopril Sodium	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error